Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.
Open accessAbstract
Several lines of evidence indicate that the nuclear receptor corepressor (N-CoR) complex imposes ligand dependence on transcriptional activation by the retinoic acid receptor and mediates the inhibitory effects of estrogen receptor antagonists, such as tamoxifen, suppressing a constitutive N-terminal, Creb-binding protein/coactivator complex-dependent activation domain. Functional interactions between specific receptors and N-CoR or SMRT corepressor complexes are regulated, positively or negatively, by diverse signal transduction pathways. Decreased levels of N-CoR correlate with the acquisition of tamoxifen resistance in a mouse model system for human breast cancer. Our data suggest that N-CoR- and SMRT-containing complexes act as rate-limiting components in the actions of specific nuclear receptors, and that their actions are regulated by multiple signal transduction pathways.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NCoR is a corepressor for androgen and estrogen receptors.
“Since then, it has been shown to be a corepressor molecule for androgen and estrogen receptors (19 -21).”
From The Nuclear Receptor Corepressor Has Organizational Effects within the Developing Amygdala on Juvenile Social Play and Anxiety-Like Behavior (2010) · cites this paper as [21]
NCoR appears to interact with both androgen and estrogen receptors.
“Because NCoR appears to interact with both androgen (19,20) and estrogen receptors (21), it is possible that reducing NCoR expression enhances the function of both nuclear receptors to further masculinize juvenile social play.”
From The Nuclear Receptor Corepressor Has Organizational Effects within the Developing Amygdala on Juvenile Social Play and Anxiety-Like Behavior (2010) · cites this paper as [21]
Cites
The nuclear receptor superfamily: the second decade
Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90199-x · Cited by 6,964 · see citing works
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829 · see citing works
Nuclear protein CBP is a coactivator for the transcription factor CREB
Kwok, R. P. S., Lundblad, J. R., Chrivia, J. C., Richards, J. P., Bächinger, H. P., Brennan, R. G., Roberts, S. G. E., Green, M. R., & Goodman, R. H. (1994) · Nature · doi:10.1038/370223a0 · Cited by 1,443 · see citing works
Nuclear Receptor Repression Mediated by a Complex Containing SMRT, mSin3A, and Histone Deacetylase
Nagy, L., Kao, H.-Y., Chakravarti, D., Lin, R. J., Hassig, C. A., Ayer, D. E., Schreiber, S. L., & Evans, R. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80218-4 · Cited by 1,230 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
The development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · see citing works
“asp?DrugCode=1%2D3926&DrugName=TAMOXIFEN+CITRATE+ORAL&DrugType=1">tamoxifen ( Box 3 ) in patients with breast cance”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233 · see citing works
“Thyroid hormone-resistance syndromes can be correlated with mutations in the LBD of TR b that enhance ligand-independent interactions anti N-CoR/SMRT (Yoh et al. 1997).”
BackgroundInfluentialSelf-citationMechanisms of estrogen action.
Nilsson, S., Mäkelä, S., Treuter, E., Tujague, M., Thomsen, J., Andersson, G., Enmark, E., Pettersson, K., Warner, M., & Gustafsson, J.-Å. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.4.1535 · Cited by 2,059 · see citing works
Nuclear Receptor Coregulators: Cellular and Molecular Biology
McKenna, N. J., Lanz, R. B., & O’Malley, B. W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.3.0366 · Cited by 1,905 · see citing works
Estrogen receptors: how do they signal and what are their targets
Heldring, N., Pike, A., Andersson, S., Matthews, J., Cheng, G., Hartman, J., Tujague, M., Ström, A., Treuter, E., Warner, M., et al. (2007) · Physiological Reviews · doi:10.1152/physrev.00026.2006 · Cited by 1,857 · see citing works
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780 · see citing works
Cofactor Dynamics and Sufficiency in Estrogen Receptor–Regulated Transcription
Shang, Y., Hu, X., DiRenzo, J., Lazar, M. A., & Brown, M. A. (2000) · Cell · doi:10.1016/s0092-8674(00)00188-4 · Cited by 1,647 · see citing works
“Consistent with insufficient to exert the cell proliferating properties of es- trogen in breast cancer. vitro studies (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998), TAM-bound ERa did recruit nuclear receptor corepressors N-CoR and SMRT to theDiscussion promoters as well.”
BackgroundCombinatorial Control of Gene Expression by Nuclear Receptors and Coregulators
McKenna, N. J., & O'Malley, B. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00641-4 · Cited by 1,463 · see citing works
Shou, J., Massarweh, S., Osborne, C., Wakeling, A., Ali, S., Weiss, H., & Schiff, R. (2004) · Journal of the National Cancer Institute · doi:10.1093/jnci/djh166 · Cited by 1,236 · see citing works
“Blocking ERK1,2 MAPK also blocks phosphorylation of NCoR and restores its nuclear localization (26), thereby increasing its availability to bind and repress ER ( 27 ,28).”
BackgroundSelf-citationMECHANISMS OF ENDOCRINE RESISTANCE IN BREAST CANCER
Osborne, C., & Schiff, R. (2011) · Annual Review of Medicine · doi:10.1146/annurev-med-070909-182917 · Cited by 1,205 · see citing works
Self-citationCoactivator and corepressor complexes in nuclear receptor function
Xu, L., Glass, C. K., & Rosenfeld, M. G. (1999) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(99)80021-5 · Cited by 897 · see citing works
Self-citationEndocrine-responsive breast cancer and strategies for combating resistance
Ali, S., & Coombes, R. C. (2002) · Nature reviews. Cancer · doi:10.1038/nrc721 · Cited by 867 · see citing works
“Tamoxifen-bound ER interacts with NCORs, resulting in repression of its agonist activit”
BackgroundEstrogen receptor pathways to AP-1.
Kushner, P., Agard, D., Greene, G., Scanlan, T., Shiau, A., Uht, R., & Webb, P. (2000) · Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00108-4 · Cited by 953 · see citing works
“It exploits the recent and striking finding that ER can bind corepressors such as N-CoR, but only in the presence of SERMs [38,39].”
BackgroundAndrogen Receptor (AR) Coregulators: An Overview
Heinlein, C. A., & Chang, C. (2002) · Endocrine Reviews · doi:10.1210/edrv.23.2.0460 · Cited by 943 · see citing works
“However, both NCoR and SMRT interact with ER when bound to the mixed agonist tamoxifen, an ER ligand that acts as an agonist or antagonist in a tissue-specific manner, and overexpression of either corepressor abolishes tamoxifen agonist activity (288).”
BackgroundInfluentialCoregulator Function: A Key to Understanding Tissue Specificity of Selective Receptor Modulators
Smith, C. L., & O’Malley, B. W. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0023 · Cited by 931 · see citing works
“For instance, in breast cancer cells, phosphorylation of Ser(118) in human ER leads to reduced interaction with the SMRT corepressor (119), whereas another laboratory has demonstrated that this posttranslational modification is required for the interaction of this receptor with the amino-terminal-specific coactivator,…”
BackgroundSuppression of Raf-1 kinase activity and MAP kinase signalling by RKIP
Yeung, K. C., Seitz, T., Li, S.-F., Janosch, P., McFerran, B., Kaiser, C., Fee, F., Katsanakis, K. D., Rose, D., Mischak, H., et al. (1999) · Nature · doi:10.1038/43686 · Cited by 909 · see citing works
Self-citationOverview of resistance to systemic therapy in patients with breast cancer
Gonzalez-Angulo, A. M., Morales-Vasquez, F., & Hortobagyi, G. N. (2007) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-74039-3_1 · Cited by 904 · see citing works
De Bosscher, K., Vanden Berghe, W., & Haegeman, G. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0006 · Cited by 898 · see citing works
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux
Synold, T. W., Dussault, I., & FORMAN, B. M. (2001) · Nature Medicine · doi:10.1038/87912 · Cited by 840 · see citing works
Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
Campbell, R., Bhat-Nakshatri, P., Patel, N., Constantinidou, D., Ali, S., & Nakshatri, H. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010840200 · Cited by 880 · see citing works
Estrogen signaling: a subtle balance between ER alpha and ER beta.
Matthews, J., & Gustafsson, J. (2003) · Molecular Interventions · doi:10.1124/mi.3.5.281 · Cited by 844 · see citing works
Osborne, C., Bardou, V., Hopp, T. A., Chamness, G., Hilsenbeck, S., Fuqua, S., Wong, J., Allred, D., Clark, G., & Schiff, R. (2003) · Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 831 · see citing works
Self-citationOverview of nomenclature of nuclear receptors
Germain, P., Staels, B., Dacquet, C., Spedding, M., & Laudet, V. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.2 · Cited by 688 · see citing works
“…it has been shown that some antagonists significantly enhance this interaction, as well as HDAC recruitment, at certain ER (cid:1) target promoters (Jackson et al., 1997; Lavinsky et al., 1998; Zhang et al., 1998; Shang et al., 2000; Yamamoto et al., 2001; Shang and Brown, 2002; Webb et al., 2003).”
BackgroundJeselsohn, R., Yelensky, R., Buchwalter, G., Frampton, G., Meric-Bernstam, F., Gonzalez-Angulo, A. M., Ferrer-Lozano, J., Perez-Fidalgo, J. A., Cristofanilli, M., Gómez, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2332 · Cited by 674 · see citing works
“org Clin Cancer Res; 20(7) April 1, 2014 1763”
BackgroundInfluentialSteroid hormone receptors: an update
Beato, M. (2000) · Human Reproduction Update · doi:10.1093/humupd/6.3.225 · Cited by 615 · see citing works
“The same proteins are also implicated in SH action as it was demonstrated that overexpression of N-CoR and SMRT represses the partial agonistic activity of both ERα bound to the anti-hormone tamoxifen and of PR bound to the antagonist RU486 (Jackson et al., 1997; Lavinsky et al., 1998).”
BackgroundMechanisms of tamoxifen resistance
Ring, A., & Dowsett, M. (2004) · Endocrine-Related Cancer · doi:10.1677/erc.1.00776 · Cited by 651 · see citing works
PPARγ, the ultimate thrifty gene
Auwerx, J. (1999) · Diabetologia · doi:10.1007/s001250051268 · Cited by 612 · see citing works
“Notably, microinjection of antibodies directed against SMRT was able to relieve SMRT corepression of PPAR's activity but antibodies directed against the related nuclear receptor corepressor were ineffective [140].”
BackgroundInfluentialEcdysone receptors and their biological actions
Riddiford, L. M., Cherbas, P., & Truman, J. W. (2000) · Vitamins & Hormones · doi:10.1016/s0083-6729(00)60016-x · Cited by 605 · see citing works
Baek, S. H., Ohgi, K., Rose, D., Koo, E., Glass, C., & Rosenfeld, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00809-7 · Cited by 591 · see citing works
Self-citationArpino, G., Wiechmann, L., Osborne, C., & Schiff, R. (2008) · Endocrine reviews · doi:10.1210/er.2006-0045 · Cited by 574 · see citing works
Self-citationCombinatorial roles of the nuclear receptor corepressor in transcription and development.
Jepsen, K., Hermanson, O., Onami, T. M., Gleiberman, A., Lunyak, V., Mcevilly, R., Kurokawa, R., Kumar, V., Liu, F. C., Seto, E., et al. (2000) · Cell · doi:10.1016/s0092-8674(00)00064-7 · Cited by 545 · see citing works
“…(Neuman et al., 1995), was was performed as previously described using anti-rabbit antibodiesupregulated in the outer layers of neocortex of N-CoR2/2 to N-CoR (Heinzel et al., 1997) or anti-guinea pig antibodies to SMRTembryos identifies MAP2 as a putative target gene for (Lavinsky et al., 1998).”
BackgroundInfluentialSelf-citationMolecular determinants of nuclear receptor-corepressor interactionPreprint
Perissi, V., Staszewski, L. M., McInerney, E. M., Kurokawa, R., Krones, A., Rose, D. W., L., L. M., Milburn, M. V., Glass, C. K., & Rosenfeld, M. G. (1999) · Genes & Development · doi:10.1101/gad.13.24.3198 · Cited by 514 · see citing works
“…of antagonists (Vegeto et al. 1992; Lanz and Rusconi 1994; Xu et al 1996; Jackson et al. 1997; Smith et al. 1997; Lavinsky et al. 1998; Wagner et al. 1998; Zhang et al. 1998a,b), and these interactions appear to be essential for full antagonist activity (Lavinsky et al. 1998; Norris et al. 1999).”
BackgroundSelf-citationBiology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
Cui, X.-J., Schiff, R., Arpino, G., Osborne, C., & Lee, A. V. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.004 · Cited by 527 · see citing works
Self-citationEstrogen receptor interaction with co-activators and co-repressors☆
Klinge, C. M. (2000) · Steroids · doi:10.1016/s0039-128x(99)00107-5 · Cited by 489 · see citing works
Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling
Clarke, R., Liu, M. C., Bouker, K., Gu, Z.-P., Lee, R., Zhu, Y., Skaar, T., Gomez, B. P., O'Brien, K. A., Wang, Y., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206937 · Cited by 514 · see citing works
“Expression of the corepressor N-CoR is lower in TAM-stimulated MCF-7 xenografts than in wildtype xenografts (Lavinsky et al., 1998), but the functional relevance of the observation in human cancers is unclear.”
BackgroundTremblay, A., Tremblay, G., Labrie, F., & Giguère, V. (1999) · Molecules and Cells · doi:10.1016/s1097-2765(00)80479-7 · Cited by 514 · see citing works
Coregulator codes of transcriptional regulation by nuclear receptors
Rosenfeld, M. G., & Glass, C. K. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.r100041200 · Cited by 509 · see citing works
Self-citationEstrogen receptor phosphorylation.
Lannigan, D. (2003) · Steroids · doi:10.1016/s0039-128x(02)00110-1 · Cited by 490 · see citing works
“[84] Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R, et al.”
BackgroundWijayaratne, A., & McDonnell, D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101097200 · Cited by 458 · see citing works
The Epigenetics of Sex Differences in the Brain
McCarthy, M., Auger, A., Bale, T., de Vries, G. J., Dunn, G. A., Forger, N., Murray, E. K., Nugent, B. M., Schwarz, J., & Wilson, M. E. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3331-09.2009 · Cited by 451 · see citing works
“It was then found to be a corepressor molecule for androgen and estrogen receptors (Lavinsky et al., 1998; Yoon and Wong, 2006).”
BackgroundStructure–function relationship of estrogen receptor α and β: Impact on human health
Ascenzi, P., Bocedi, A., & Marino, M. (2006) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.07.001 · Cited by 503 · see citing works
Selective Estrogen Receptor Modulators
Frasor, J., Stossi, F., Danes, J. M., Komm, B., Lyttle, C., & Katzenellenbogen, B. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3326 · Cited by 447 · see citing works
PPARγ AND G LUCOSE H OMEOSTASIS
Picard, F., & Auwerx, J. H. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.010402.102808 · Cited by 412 · see citing works
Patel, H., & Bihani, T. (2017) · Pharmacology and Therapeutics · doi:10.1016/j.pharmthera.2017.12.012 · Cited by 423 · see citing works
Cellular and molecular pharmacology of antiestrogen action and resistance.
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 421 · see citing works
Estrogen receptor mutations in human disease.
Herynk, M. H., & Fuqua, S. (2004) · Endocrine reviews · doi:10.1210/er.2003-0010 · Cited by 419 · see citing works
Webb, P., Nguyen, P. T., Valentine, C. D., Lopez, G. N., Kwok, G. R., McInerney, E. M., Katzenellenbogen, B. S., Enmark, E., Gustafsson, J.-Α., Nilsson, S. V., et al. (1999) · Molecular Endocrinology · doi:10.1210/mend.13.10.0357 · Cited by 391 · see citing works
Estrogen receptor (ER) modulators each induce distinct conformational changes in ER α and ER β
Paige, L. A., Christensen, D. J., Grøn, H., Norris, J. D., Gottlin, E. B., Padilla, K. M., Chang, C., Ballas, L. M., Hamilton, P. T., McDonnell, D. P., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3999 · Cited by 410 · see citing works
Wang, C., Fu, M., Angeletti, R. H., Siconolfi-Baez, L., Reutens, A. T., Albanese, C., Lisanti, M. P., Katzenellenbogen, B. S., Kato, S., Hopp, T., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100800200 · Cited by 365 · see citing works
Ricote, M., Huang, J. T., Welch, J., & Glass, C. (1999) · Journal of Leukocyte Biology · doi:10.1002/jlb.66.5.733 · Cited by 392 · see citing works
Self-citationSelective estrogen receptor modulators: structure, function, and clinical use.
Osborne, C. K., Zhao, H., & Fuqua, S. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3172 · Cited by 382 · see citing works
Self-citationEstrogen Receptor Activation Function 1 Works by Binding p160 Coactivator Proteins
Webb, P., Nguyen, P. T., Shinsako, J., Anderson, C. M., Feng, W., Nguyen, M. P., Chen, D., Huang, S.-M., Subramanian, S., McKinerney, E., et al. (1998) · Molecular Endocrinology · doi:10.1210/mend.12.10.0185 · Cited by 382 · see citing works
“Our study complements a recently published study which shows that microinjection of anti-p160 or anti-CBP antibodies block tamoxifen response in cells (HepG2) where AF-1 activity is high (62).”
BackgroundThe histone deacetylase-3 complex contains nuclear receptor corepressors
Wen, Y.-D., Perissi, V., Staszewski, L. M., Yang, W.-M., Krones, A., Glass, C. K., Rosenfeld, M. G., & Seto, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.13.7202 · Cited by 378 · see citing works
Self-citationPhosphorylation of the Nuclear Receptor SF-1 Modulates Cofactor Recruitment
Hammer, G. D., Krylova, I., Zhang, Y., Darimont, B. D., Simpson, K., Weigel, N. L., & Ingraham, H. A. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80480-3 · Cited by 375 · see citing works
Scarpin, K. M., Graham, J., Mote, P., & Clarke, C. (2009) · Nuclear Receptor Signaling · doi:10.1621/nrs.07009 · Cited by 374 · see citing works
“Decreased expression of these corepressors may contribute to the tamoxifen resistance phenotype [Lavinsky et al., 1998; Smith et al., 1997].”
Nuclear Hormone Receptor Coregulators In Action: Diversity For Shared Tasks
Robyr, D., Wolffe, A. P., & Wahli, W. (2000) · Molecular Endocrinology · doi:10.1210/mend.14.3.0411 · Cited by 378 · see citing works
Non-genomic actions of estrogens and their interaction with genomic actions in the brain.
Vasudevan, N., & Pfaff, D. (2008) · Frontiers in neuroendocrinology (Print) · doi:10.1016/j.yfrne.2007.08.003 · Cited by 360 · see citing works
Arnal, J., Lenfant, F., Métivier, R., Flouriot, G., Henrion, D., Adlanmérini, M., Fontaine, C., Gourdy, P., Chambon, P., Katzenellenbogen, B. S., et al. (2017) · Physiological Reviews · doi:10.1152/physrev.00024.2016 · Cited by 428 · see citing works
Structural insights into the mode of action of a pure antiestrogen.
Pike, A., Brzozowski, A., Walton, J., Hubbard, R., Thorsell, A., Li, Y.-L., Gustafsson, J.-Å., & Carlquist, M. (2001) · Structure · doi:10.1016/s0969-2126(01)00568-8 · Cited by 353 · see citing works
Interdomain communication regulating ligand binding by PPAR-γ
Shao, D., Rangwala, S. M., Bailey, S., Krakow, S. L., Reginato, M., & Lazar, M. (1998) · Nature · doi:10.1038/24634 · Cited by 347 · see citing works
Vivacqua, A., Bonofiglio, D., Recchia, A., Musti, A., Picard, D., Andò, S., & Maggiolini, M. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0280 · Cited by 345 · see citing works
“In addition, an altered expression of ER coregulators has been associated with the progression of breast cancers toward a more malignant and TAM-resistant phenotype (26).”
BackgroundNuclear receptor coregulators: multiple modes of modification.
Hermanson, O., Glass, C., & Rosenfeld, M. (2002) · Trends in endocrinology and metabolism · doi:10.1016/s1043-2760(01)00527-6 · Cited by 341 · see citing works
Self-citationEstrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance
Ali, S., & Coombes, R. (2000) · Journal of mammary gland biology and neoplasia · doi:10.1023/a:1009594727358 · Cited by 336 · see citing works
The role of corepressors in transcriptional regulation by nuclear hormone receptors.
Privalsky, M. (2004) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.155556 · Cited by 335 · see citing works
Collingwood, T., Urnov, F. D., & Wolffe, A. P. (1999) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0230255 · Cited by 318 · see citing works
“The ER can also bind the NCoR and SMRT corepressors in the presence of antagonists such as tamoxifen and RU486 (Laherty et al. 1998, Lavinsky et al. 1998).”
Underhill, C., Qutob, M. S., Yee, S.-P., & Torchia, J. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007864200 · Cited by 323 · see citing works
Self-citationMolecular mechanisms of selective estrogen receptor modulator (SERM) action.
Dutertre, M., & Smith, C. L. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38923-2 · Cited by 320 · see citing works
“Moreover, in cells in which tamoxifen is an antagonist, tamoxifen, but not estradiol, enhances ER interactions with N-CoR (Lavinsky et al., 1998).”
InfluentialThe Molecular Pharmacology of SERMs.
McDonnell, D. P. (1999) · Trends in endocrinology and metabolism · doi:10.1016/s1043-2760(99)00177-0 · Cited by 317 · see citing works
A Tissue-Specific Coactivator of Steroid Receptors, Identified in a Functional Genetic Screen
Knutti, D., Kaul, A., & Kralli, A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.7.2411-2422.2000 · Cited by 286 · see citing works
“Among them, corepressors such as SMRT and NcoR bind to receptors in the absence of hormone or the presence of an antagonist ligand, connect the receptors to histone deacetylases, and promote the silencing of neighboring promoters (9, 21, 23, 35, 51).”
BackgroundKatzenellenbogen, B., & Katzenellenbogen, J. (2000) · Breast Cancer Research · doi:10.1186/bcr78 · Cited by 313 · see citing works
Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer.
Normanno, N., di Maio, M., Maio, E. D., Luca, A. D., de Matteis, A., Giordano, A., & Perrone, F. (2005) · Endocrine-Related Cancer · doi:10.1677/erc.1.00857 · Cited by 306 · see citing works
“In addition, it has been shown that tamoxifen interacts with co-repressors when bound to ER, and that this mechanism is involved in the suppression of transcription (Lavinsky et al .”
BackgroundCoregulators in Nuclear Estrogen Receptor Action: From Concept to Therapeutic Targeting
Hall, J. M. (2005) · Molecular Interventions · doi:10.1124/mi.5.6.7 · Cited by 291 · see citing works
Estrogen receptors as therapeutic targets in breast cancer.
Ariazi, E. A., Ariazi, J. L., Cordera, F., & Jordan, V. (2006) · Current Topics in Medicinal Chemistry · doi:10.1002/9783527623297.ch5 · Cited by 303 · see citing works
Jakacka, M., Ito, M., Weiss, J., Chien, P.-Y., Gehm, B. D., & Jameson, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m008384200 · Cited by 299 · see citing works
Saccharomyces cerevisiae telomerase is an Sm small nuclear ribonucleoprotein particle
Seto, A., Zaug, A., Sobel, S. G., Wolin, S., & Cech, T. (1999) · Nature · doi:10.1038/43694 · Cited by 298 · see citing works
Signal-specific co-activator domain requirements for Pit-1 activation
Xu, L., Lavinsky, R. M., Dasen, J., Flynn, S. E., McInerney, E., Mullen, T., Heinzel, T., Szeto, D. P., Korzus, E., Kurokawa, R., et al. (1998) · Nature · doi:10.1038/26270 · Cited by 298 · see citing works
“The observation that 4- trans -hydroxytamoxifen (TOT), an antagonist of the oestrogen receptor, but not the agonist 17-β-oestradiol, induces N-CoR interaction with the oestrogen recepto”
BackgroundSelf-citationTranscriptional repression by nuclear hormone receptors.
Hu, X., & Lazar, M. (2000) · Trends in endocrinology and metabolism · doi:10.1016/s1043-2760(99)00215-5 · Cited by 297 · see citing works
Htun, H., Holth, L. T., Walker, D., Davie, J., & Hager, G. (1999) · Molecular Biology of the Cell · doi:10.1091/mbc.10.2.471 · Cited by 297 · see citing works
Ligand control of coregulator recruitment to nuclear receptors.
Nettles, K., & Greene, G. (2005) · Annual Review of Physiology · doi:10.1146/annurev.physiol.66.032802.154710 · Cited by 283 · see citing works
Phosphorylation of Steroid Receptor Coactivator-1
Rowan, B. G., Weigel, N. L., & O’Malley, B. W. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.6.4475 · Cited by 267 · see citing works
Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length
Irvine, R. A. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.2.267 · Cited by 263 · see citing works
“Recently, however, it was revealed that p160 coactivators interact with the NTDs of the estrogen receptor (ER) (35, 36 ), the progesterone receptor (PR) (37) and the AR (38) in addition to binding to their respective LBDs.”
BackgroundDilworth, F. J., & Chambon, P. (2001) · Oncogene · doi:10.1038/sj.onc.1204329 · Cited by 269 · see citing works
“…ligands to either ER or PR permit the binding of the homodimers to their respective response elements in vivo without inducing an active AF-2, further demonstrating that this activation function does not play a role in receptor binding to the template (Lavinsky et al., 1998; Smith et al., 1997).”
BackgroundAlen, P., Claessens, F., Verhoeven, G., Rombauts, W., & Peeters, B. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.6085 · Cited by 268 · see citing works
Zhu, P., Baek, S. H., Bourk, E., Ohgi, K., Garcia-Bassets, I., Sanjo, H., Akira, S., Kotol, P., Glass, C., Rosenfeld, M., et al. (2006) · Cell · doi:10.1016/j.cell.2005.12.032 · Cited by 268 · see citing works
“Based on genetic analyses, N-CoR proves to be required for the inhibitory function of estrogen receptor (ER) antagonists (SERMs) (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998; reviewed in Glass and Rosenfeld, 2000; McKenna and O’Malley, 2002).”
Self-citationThe PGC-1-related Protein PERC Is a Selective Coactivator of Estrogen Receptor α
Kressler, D., Schreiber, S., Knutti, D., & Kralli, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201134200 · Cited by 239 · see citing works
Rowan, B. G., Garrison, N., Weigel, N. L., & O’Malley, B. W. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.23.8720-8730.2000 · Cited by 244 · see citing works
García-Becerra, R., Santos, N. D., Díaz, L., & Camacho, J. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms14010108 · Cited by 261 · see citing works
“In a xenograft model for human breast cancer, NCoR levels decreased in the tumors that acquired resistance to tamoxifen [230].”
BackgroundGurnell, M., Wentworth, J. M., Agostini, M., Adams, M., Collingwood, T., Provenzano, C., Browne, P. O., Rajanayagam, O., Burris, T. P., Schwabe, J. W., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5754 · Cited by 260 · see citing works
The pleiotropic functions of peroxisome proliferator-activated receptor γ
Debril, M.-B., Renaud, J., Lluis Fajas, A., & Auwerx, J. H. (2000) · Journal of Molecular Medicine · doi:10.1007/s001090000145 · Cited by 220 · see citing works
Yu, C., Markan, K. R., Temple, K. A., Deplewski, D., Brady, M., & Cohen, R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409468200 · Cited by 243 · see citing works
Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis.
Fajas, L., Debril, M.-B., & Auwerx, J. (2001) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0270001 · Cited by 242 · see citing works
Kawai, H., Li, H.-C., Avraham, S., Jiang, S.-X., & Avraham, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11403 · Cited by 241 · see citing works
BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor
Zheng, L., Annab, L., Afshari, C., Lee, W.-H., & Boyer, T. (2001) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.171174298 · Cited by 241 · see citing works
Oestrogen-receptor-mediated transcription and the influence of co-factors and chromatin state
Green, K., & Carroll, J. (2007) · Nature Reviews. Cancer · doi:10.1038/nrc2211 · Cited by 235 · see citing works
“, and NCOR1 levels are reduced in mouse models of tamoxifen resistanc”
BackgroundBhardwaj, P., Au, C. C., Benito-Martin, A., Ladumor, H., Oshchepkova, S., Moges, R., & Brown, K. A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.002 · Cited by 233 · see citing works
Membrane-Initiated Actions of Estrogens in Neuroendocrinology: Emerging Principles
Vasudevan, N., & Pfaff, D. W. (2007) · Endocrine Reviews · doi:10.1210/er.2005-0021 · Cited by 231 · see citing works
“This is possibly because phosphorylation of nuclear receptors appears to enhance interaction with coactivators (188).”
BackgroundLaherty, C. D., Billin, A., Lavinsky, R. M., Yochum, G., Bush, A. C., Sun, J.-M., Mullen, T., Davie, J. R., Rose, D., Glass, C. K., et al. (1998) · Molecules and Cells · doi:10.1016/s1097-2765(00)80111-2 · Cited by 231 · see citing works
Self-citationHDAC3: taking the SMRT-N-CoRrect road to repression
Karagianni, P., & Wong, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210612 · Cited by 228 · see citing works
“In other examples, it is the antagonist-bound receptor that interacts with N-CoR/ SMRT to repress transcription (Jackson et al., 1997; Smith et al., 1997; Lavinsky et al., 1998).”
Prolactin modulation of immune and inflammatory responses.
Yu-Lee, L. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.435 · Cited by 222 · see citing works
“, by changing an estrogen antagonist into an agonist) (Lavinsky et al., 1998; McDonnell, 1999).”
Gelman, L., Fruchart, J., & Auwerx, J. (1999) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050345 · Cited by 219 · see citing works
- Authors
- Lavinsky, R. M., Jepsen, K., Heinzel, T., Torchia, J., Mullen, T.-M., Schiff, R., Del-Rio, A. L., Ricote, M., Ngo, S., Gemsch, J., Hilsenbeck, S. G., Osborne, C. K., Glass, C. K., Rosenfeld, M. G., & Rose, D. W.
- Affiliations
- Howard Hughes Medical Institute (US)
- Howard Hughes Medical Institute, Cellular and Molecular Medicine, Whittier Diabetes Program, and UCSD Graduate Program in Biology, Department and School of Medicine, University of California at San Diego, La Jolla, CA 92093-0648; and Department of Medicine, Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, TX 78284-7884
- Corresponding author
- Rose, David W.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1998-03-17
- Volume
- 95
- Issue
- 6
- Pages
- 2920-2925
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC19670
- OpenAlex
- W2128003724
- Cited by
- 660
- References
- 52
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 10 · 2021: 6 · 2020: 10 · 2019: 13 · 2018: 10 · 2017: 11 · 2016: 13 · 2015: 15 · 2014: 13 · 2013: 12 · 2012: 20
- FWCI
- 30.37
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Science Foundation
- Howard Hughes Medical Institute
- American Diabetes Association
- National Institutes of Health
- National Cancer Institute (P30CA 54174, P30CA054174, P50 CA58183, P50CA058183)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- nuclear receptor corepressor, SMRT, signaling pathways, retinoic acid receptor, estrogen receptor, tamoxifen resistance, breast cancer, transcriptional repression, ligand-dependent transcription, CREB-binding protein, coactivator complexes
- MeSH terms
- Animals, Breast Neoplasms, Disease Models, Animal, DNA-Binding Proteins, Drug Resistance, Estrogen Antagonists, Gene Expression Regulation, Humans, Models, Biological, Nuclear Proteins, Protein Binding, Protein Kinases, Receptors, Estrogen, Repressor Proteins, Tamoxifen, Signal Transduction, Genes, Reporter, Receptors, Retinoic Acid, Mice, Nuclear Receptor Co-Repressor 1, Nuclear Receptor Co-Repressor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
